Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
$262K Sell
42,160
-18,445
-30% -$671K 3.96% 6
2019
Q2
$176K Buy
60,605
+42,160
+229% +$1.67M 3.27% 7
2019
Q1
$83K Sell
18,445
-329,691
-95% -$13.2M 1.16% 8
2018
Q4
$623K Sell
348,136
-26,139
-7% -$1.09M 2.29% 14
2018
Q3
$110K Sell
374,275
-60,816
-14% -$2.34M 0.17% 87
2018
Q2
$297K Sell
435,091
-421,600
-49% -$14.4M 0.45% 39
2018
Q1
$749K Buy
856,691
+158,100
+23% +$5.44M 0.51% 17
2017
Q4
$436K Buy
698,591
+276,991
+66% +$9.44M 0.3% 26
2017
Q3
$122K Buy
+421,600
New +$13.6M 0.08% 215

Other funds holding PFE

TLP Group's PFE Position: Q3 2019 in Review

TLP Group reduced its Pfizer (PFE) stake by 95% in Q3 2019, selling an estimated $8.24M and leaving 12,016 shares worth $410K. The position accounts for 6.2% of the portfolio, ranked #5.

TLP Group first reported a position in PFE in Q4 2015 and has held it in 10 quarters since. The position peaked at $3.79M in Q4 2017. 2,322 funds tracked by Wall St. Rank hold PFE as of Q3 2019.

  • TLP Group held 12,016 shares of Pfizer worth $410K as of Q3 2019.
  • TLP Group sold 226,715 Pfizer shares in Q3 2019, an estimated $8.24M.
  • Pfizer made up 6.2% of TLP Group's portfolio in Q3 2019, its #5 holding.
  • TLP Group first reported a position in Pfizer in Q4 2015 and has held it in 10 quarters since.
  • TLP Group's Pfizer position peaked at $3.79M in Q4 2017.
  • 2,322 funds tracked by Wall St. Rank held Pfizer as of Q3 2019.

Based on TLP Group's 13F filing for Q3 2019, filed 11 Oct 2019.